Hi BASIAC, Thanks for sharing. PNV are not on the list to watch,...

Hi BASIAC, Thanks for sharing. PNV are not on the list to watch, however they are mentioned within the article, see below:

Page 4. Australian biotechnology developments include the Cochlear implant now being sold by Cochlear globally and Resmed’s (RMD) CPAP device helping many people with sleep apnoea.Other home-grown technologies occupying a spot on the world stage include a disinfection system for ultrasound probes by Nanosonics (NAN) and Polynovo’s (PNV) synthetic absorbable polymers.

Page 8.
Hester says companies that raised money in 2020-2021 are sitting pretty, pointing to Avita Medical (AVH) and Polynovo (PNV) as examples.“Avita is still burning cash at quite a rate, but it’s held up really well because it’s got plenty of cash in the bank, and also a bit of revenue,” he said.“Polynovo doesn’t have a lot of cash in the bank but, similarly, it does have strong revenue growth. “In contrast, a stock like Aroa Biosurgery (ARX) which has ~$50 million in the bank, is not yet A re-capitalisation cycle is imminent, says Bell Potter healthcare analyst John Hester, and health and biotech stocks with cash in the bank will sit ahead of the packHow to catch the biotech bounce backEmma Davies cashfow positive, but has held up really well.

In my opinion, Polynovo is too established to be included in this list.